Influenza Vaccines Market Research Report - Global Forecast till 2027

Influenza Vaccines Market: Information by Influenza Type (Seasonal and Zoonotic), by Manufacturing Technology (Egg-based, Cell culture-based and Recombinant-based), by Vaccine Type ( Quadrivalent Influenza Vaccines and Trivalent Influenza Vaccines) by End User (Hospitals & Clinics, Research Organizations & Academic Institutes, and others) and by Region (Americas, Europe, Asia-Pacific, and the Middle East & Africa) - Forecast till 2027

ID: MRFR/Pharma/1090-CR | February 2021 | Region: Global | 148 pages

Influenza Vaccines Market Overview:
The global influenza vaccines market is predicted to reach USD 7,828.3 Million by 2025 to register a CAGR of 6.53%.  The influenza virus is a very common and deadly viral infection with the potential of infecting the respiratory system of human beings. The influenza virus is a contagious respiratory illness that affects the lungs, nose, and throat.  People who have week immunity systems or who have chronic diseases are at high risks. It is a viral disease that spreads from one person to another in oozing of the lungs and nose.

Vaccines work with the body’s natural defense to fabricate protection by reducing the risks of getting infected. A vaccine helps to produce the antibodies in the immunity system to fight the diseases. One or more doses of the vaccine typically protect against the diseases for a few years, decades, or maybe even for a lifetime. There is mostly two influenza vaccine type which is widely available in the market, these are inactivated influenza vaccine (IIV) and live attenuated influenza vaccines (LAIV). These vaccines are made to protect against three seasonal viruses. Influenza viruses are a threat to the human population, under the major public health estimation; vaccinations are the ultimate prevention from the disease.

The influenza vaccine market size is estimated to reach nearly $6.20 Billion by the end of 2026; it was estimated at nearly $3.96 Billion in the year 2018, with an increasing annual growth rate of 5.9% (CAGR) in between 2019 to 2026. According to the static data from the centers for disease control and prevention, there are more than 13 million flu cases that are documented till now, in between the time frame of 2019 to 2020. Depending on the current scenario of the vaccine market, the licensed seasonal vaccines are recommended by government organizations, centers for disease control and prevention, and by the world health organization. Pharmaceutical companies are continuously working on improving the condition of the vaccines against different infections. The urge of rising demands increases the global influenza vaccine market value.

This report focuses on the all-inclusive global flu vaccine market and the strength of the influenza vaccine market. Along with that, the report contains the high points of dynamics, segmentation, key players, regional analysis, and many other factors. The report also included a detailed analysis of the influenza vaccine globally and forecasts to 2025.

Covid 19 Analysis:
The increasing demand for vaccines has bolstered the growth of the influenza market size. The outbreak of the pandemic has affected the countries around the globe tremendously; this has affected the global market of vaccination. There is a rise in the demand for vaccines globally because of the effectiveness of the doses against the disease or infection. There was a report issued at the starting of the year 2020 by Pfizer. Inc that there were no disturbances accrued in the supply chain of these vaccines in fact the emission of covid 19 vaccines has raised the potential value of the influenza vaccine market.

According to the researchers of Brazil, these vaccine shots can help to reduce the death rates by 20 % before the inception of the covid vaccine and it can reduce about 27 % after the inception of the covid vaccine. Thus the analyst believes that these factors can toss the demand for this influenza vaccine.

Market Dynamic:

  •         Drivers

The influenza vaccine market has increased tremendously over the past few years. There is a number of factors influencing the raised market value including the increase of the awareness of the disease among the people, funding, and the fear of influenza pandemic.

There are seven major markets that have a strong amalgamation of the annual growth rate of 12.65%, it includes UK, France, Germany, the united states, Japan, Spain, and Italy.

  •         Opportunities

The government has taken the initiative to sure the well-being of the population by minimizing the side effects of the influenza vaccines. The development of new vaccines and the improvement of the existing or current vaccines are the major causes for the rise of the influenza vaccine market.

Along with that, the rise in the population, investment, and funding by different companies are also directly linked with the expansion of the influenza vaccine market growth.  

  •         Restraints

69,009 people were diagnosed in the year 2018 with the influenza virus. Among which 67,733 people have diagnosed with influenza A virus and the rest of them were diagnoses with influenza B virus. In the United States, the cases of influenza have increased from 9.2 Million cases to 49.0 million cases of infection in 2010.

The inactivated influenza vaccines (IIV) are appropriate for younger people, most probably for kids of 6 months or above. The recombinant influenza vaccine is only acceptable for adults or people aged 18 years or more. The adjuvant vaccines contain the highest doses, hence approved for older people or people aged 65 years or more.   

  •         Challenges

The influenza market is facing a number of challenges due to Covid 19 and several other seasons.  There is a specific period of time in which the seasonal vaccines should be produced and shipped; the approx time frame is of 6 months. The delays in the manufacturing of the vaccines can mislay market shares and the revenue.

The demands of the vaccine vary according to the season, weather, and timing which affect the growth in the market. The availability of influenza vaccines during the unpredictable period is the major provocation in the market. The awareness among the public is another one.

  •         Cumulative Growth Analysis

The global influenza market expected to reach up to USD 7,321.79 Million in 2025 from USD 5,563.37 Million USD in 2019 with an annual growth rate of 4.86%.

The growth on the demand depends upon the four major segments that include influenza type, technology, manufacturing, and end user. Thereafter, the market growth can get affected by a pandemic or calamitous conditions or natural disaster.  

Value Chain Analysis:
There are four segments of the influenza market that are typically based on the different influenza type, vaccine type, manufacturing technology, and end user. On the basis of the type the influenza vaccines have been bifurcated into zoonitic and seasonal. On the other hand, on the basis of manufacturing technology, the vaccine has been categorized into egg-based, cell-culture based, recombinant based. According to the type of vaccine, it is bifurcated into trivalent vaccine and quadrivalent vaccine. The end-users of the global influenza market can be research organizations, academic institutions, hospitals, and others.

The form of the dosage can be nasal spray, intramuscular injection and intradermal. The report contains the market trends related with each segment and affects of the segments on the overall growth of the global influenza vaccines market.   

Segmentation Overview:
On the basis of the end users and application the global influenza vaccines market can be categorized. According to the different products, there are two different types of vaccines; one is trivalent vaccine and quadrivalent vaccines.

  •         By Application

On the application basis, the vaccines are segmented into two types, one is trivalent vaccine which is for the kids of 6 months or above and the other one is recombinant influenza vaccine, which is for the adults or for the aged people.  

Hence, the effects of the virus changes slightly every year, that makes the vaccines of previous year less effective or ineffective. This is the major cause of the fluctuation in the global vaccine market. 

  •         By End-Users

On the basis on the End-user segmentation, the global influenza vaccination is modified by different sectors including academic institutes, clinics and hospitals, researchers and organizations, and others. 

There are chance is highest growth in the research sector during the projected period. The reason for that is the nature of the virus which is changing every year and accordingly the vaccines needs up gradation after every 6 months to 1 year.

Regional Analysis:
The influenza vaccine market is divided into four sections, based on the region and which are Europe, America, the Middle East & Africa, and Asia-pacific. The America is leading the race; it has dominated the global influenza vaccine market with an attribution of more than half of the population. Each year, 5% to 20% of the total population suffers from the influenza virus.

European markets are the second largest market for the global influenza vaccine market during the review period. The generality of the influenza and the rise in the product has boosted the growth of the regional market. The uptakes of the vaccines have increased to 72% from 2018 to 2019, from 70% from 2016 to 2017.

The Pacific-Asia has shown tremendous growth during the forecast period, the markets in the Africa and middle-east has the lowest growth rated due to the unavailability or limited access to the treatment facilities. The developing healthcare infrastructure is the major cause for the rise in growth of the market in middle-east and Africa. 

Competitive landscape:
The share, growth and influenza vaccine market size, surveys the scenarios of the market by analyzing the key players. The different strategies adopted by different companies for the extension of the business, among which mergers, acquisions and other measures of business are included. The financial framework includes profit, sales, and the revenue generated by the market’s key players.

The major key player of the influenza vaccine markets are as follows:

  •         AstraZenca (UK)

  •         GlazoSmithKline PLC (UK)

  •         Sanofi(France)

  •         Abbott Laboratories (US)

  •         Seqirus (UK)

  •         Hualan Biological Engineering Inc. (China)

  •         Mitsubishi Tanabe Pharma (Japan)

  •         Serum Institute of India Pvt. Ltd (India)

  •         Mylan NV (US)

Recent Developments

  • Recently, several new novel formulations have been tested. These formulations contain ranges of high doses of vaccines for the older people or people ages 65 or more and other adjuvented vaccines are MF59 AND AS03.

  • These new formulation has increased the efficiency of the vaccines. MF59 is a seasonal vaccine for the older people and it is licensed and marked in more than 25 countries, in the name of the brand Flaud. AS03 is still under constructions.

Report Overview:
The following report comprises of –

  •         Market overview

  •         Covid 19 Analysis

  •         Market Dynamic

  •         Drivers

  •         Opportunities

  •         Restraints

  •         Challenges

  •         Cumulative Growth Analysis

  •         Value Chain Analysis

  •         Segmentation Overview

  •         By Application

  •         By End-Users

  •         Regional Analysis

  •         Competitive landscape

  •         Recent Developments

This report is to point out the high points of the global flu vaccine market in terms of the revenue hike by end of the global forecast year 2025.

Market Segmentation:
Global Influenza Vaccines Market, by Influenza Type

  •         Seasonal

  •         zoonotic

GlGlobal Influenza Vaccines Market, by Manufacturing Technology

  •         Egg-based

  •         Cell culture based

  •         Recombinant base

Global Influenza Vaccines Market, by Vaccine Type

  •         Quadrivalent Influenza Vaccines

  •         Trivalant Influenza Vaacines

Global Influenza Vaccines Market, by End User

  •         Hospitals & Clinics

  •         Research Organizations & Academic Institutes

  •         Others

Global Influenza Vaccines Market, by Region

  •         Americas

  •         North America

  •         South America

  •         Europe

  •         UK

  •         France

  •         Germany

  •         Russia

  •         Italy

  •         Rest of Europe

  •         Asia-Pacific

  •         China

  •         India

  •         Australia

  •         New Zealand

  •         Rest of Asia-Pacific

  •         Middle East & Africa

  •         Saudi Arabia

  •         UAE

  •         Egypt

  •         Kuwait

  •         South Africa

  •         Oman

  •         Rest of Middle East & Africa

Report Scope:
Report Attribute/Metric Details
  Market Size

  • 2025: USD 7,828.3 Million
  • 2027: Significant Value
  •   CAGR   6.53% (2019-2025)
      Base Year   2019
      Forecast Period   2020-2027
      Historical Data   2018
      Forecast Units   Value (USD Million)
      Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
      Segments Covered   Influenza Type, Manufacturing Technology, Vaccine Type and End User
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors   Abbott (U.S.), AstraZeneca (Europe), BioCryst Pharmaceuticals, Inc. (U.S.), Novartis AG (Europe), DAIICHI SANKYO COMPANY, LIMITED. (Asia Pacific), GlaxoSmithKline plc. (Europe). Hualan Biological Engineering Inc (Asia Pacific), Mitsubishi Tanabe Pharma Corporation (Asia Pacific), F. Hoffmann-La Roche Ltd (Europe), Sanofi (Europe), Paxvax Corporation (U.S.)
      Key Market Opportunities   development of new vaccines and the improvement of the existing or current vaccines
      Key Market Drivers

  • increase of the awareness of the disease among the people
  • funding
  • the fear of influenza pandemic

  • Frequently Asked Questions (FAQ) :

    Influenza vaccine manufacturer takes five to six months approximately to for the first batch of the approved vaccines to become available.

    A and B viruses are the causes of the seasonal flu and C typed causes milder respiratory symptoms.